Regeneron has beaten earnings estimates in all four of the last four quarters with an average surprise of 22%, trades at a forward price-to-earnings of 11.4x with 22% analyst upside, and maintains strong net margins of 30% — but faces declining earnings estimates, weak revenue growth, and near-term technical weakness from a death cross, creating a fundamentally sound but momentum-challenged setup.
Thesis pillars
- Strong Margins And Financial Health→Stable
- Perfect Earnings Beat Streak Quality→Stable
- Attractive Valuation Versus Peers→Stable
- +1 more pillar — see the Why tab for full reasoning
Regeneron Pharmaceuticals, Inc. (REGN) Stock Analysis
Catalyst-Driven edge
Healthcare · Biotechnology
Hold if already holding. Not a fresh buy at $657.00, but acceptable to hold if already in. Reasons: Leverage penalty (D/E 8.6): -1.5; Weak growth.
Regeneron Pharmaceuticals generated $14.3 billion in total revenues in 2025, driven by U.S. EYLEA HD and EYLEA net product sales (31% of revenues) and Sanofi collaboration revenue from Dupixent (41% of revenues). The company has multiple approved products spanning ophthalmology,... Read more
Hold if already holding. Not a fresh buy at $657.00, but acceptable to hold if already in. Reasons: Leverage penalty (D/E 8.6): -1.5; Weak growth. Chart setup: No clear chart pattern; technical signals are mixed. Multiple concerning factors. Consider reducing position. | News modifier +2 (SELL_IF_HOLDING → HOLD_IF_HOLDING) Score 5.8/10, moderate confidence.
Passes 8/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news boost analyst cluster(5), earnings proximity 25d clear, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
Recent developments
updated 2026-07-07Recent Developments — Regeneron Pharmaceuticals, Inc.
Latest news
- NEWS Regeneron Stock Tumbles on Earnings. Upcoming Data Matter More for the Stock. - Barron's — Barron's negative
- NEWS Regeneron Slumps On An Unexpected Setback For Its Bread-And-Butter Drug - Investor's Business Daily — Investor's Business Daily negative
- NEWS Regeneron Slumps On Unexpected Eylea Setback - Investor's Business Daily — Investor's Business Daily negative
- NEWS Regeneron Pharmaceuticals Inc Stock (REGN) Moved Down by 7.82% on Apr 29: Facts Behind the Movement - TradingKey — TradingKey negative
- NEWS Earnings call transcript: Regeneron Q1 2026 beats estimates, stock dips - Investing.com — Investing.com positive
Generated 2026-07-07T13:52:22Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMProductEYLEA HD and EYLEA31%10-K Item 1A: 'our aggregate EYLEA HD and EYLEA net product sales in the United States represented 31%...of our total revenues'
- MEDIUMcounterpartySanofi41%10-K Item 1A: 'Sanofi collaboration revenue (most of which is attributable to our share of profits from the commercialization of Dupixent) represented 41%...of our total revenues'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $657.00, but acceptable to hold if already in. Reasons: Leverage penalty (D/E 8.6): -1.5; Weak growth. Chart setup: No clear chart pattern; technical signals are mixed. Multiple concerning factors. Consider reducing position. | News modifier +2 (SELL_IF_HOLDING → HOLD_IF_HOLDING) Target $749.98 (+14.2%), stop $619.15 (−6.1%), A.R:R 1.8:1. Score 5.8/10, moderate confidence.
Take-profit target: $749.98 (+15.4% upside). Target $749.98 (+14.2%), stop $619.15 (−6.1%), A.R:R 1.8:1. Stop-loss: $619.15.
Leverage penalty (D/E 8.6): -1.5; Weak growth.
Regeneron Pharmaceuticals, Inc. trades at a P/E of 16.0 (forward 12.2). TrendMatrix value score: 7.0/10. Verdict: Hold.
38 analysts cover REGN with a consensus score of 3.9/5. Average price target: $833.
What does Regeneron Pharmaceuticals, Inc. do?Regeneron Pharmaceuticals generated $14.3 billion in total revenues in 2025, driven by U.S. EYLEA HD and EYLEA net...
Regeneron Pharmaceuticals generated $14.3 billion in total revenues in 2025, driven by U.S. EYLEA HD and EYLEA net product sales (31% of revenues) and Sanofi collaboration revenue from Dupixent (41% of revenues). The company has multiple approved products spanning ophthalmology, immunology, oncology, and rare diseases, partnering with Sanofi and Bayer for select commercialization outside the US.